Callan Capital’s Standard BioTools LAB Stock Holding History

Callan Capital’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-17,400	Closed	-$70K	–	86
2020 Q2	$70K	Buy	17,400 +7,400	+74%	+$25.8K	0.02%	86
2020 Q1	$25K	Buy	+10,000	New	+$32.9K	0.01%	81

Other funds holding LAB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Atom Investors Austin, Texas $1.4B AUM 23.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Callan Capital's LAB Position: Q3 2020 in Review

Callan Capital sold out of Standard BioTools (LAB) in Q3 2020, closing a stake of 17,400 shares — an estimated $70K sold.

Callan Capital first reported a position in LAB in Q1 2020 and held it in 2 quarters. The position peaked at $70K in Q2 2020. 134 funds tracked by Wall St. Rank hold LAB as of Q3 2020.

Callan Capital reported no remaining Standard BioTools position as of Q3 2020 after selling out during the quarter.
Callan Capital sold 17,400 Standard BioTools shares in Q3 2020, an estimated $70K.
Callan Capital first reported a position in Standard BioTools in Q1 2020 and held it in 2 quarters.
Callan Capital's Standard BioTools position peaked at $70K in Q2 2020.
134 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2020.

Based on Callan Capital's 13F filing for Q3 2020, filed 23 Oct 2020.